Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $26.1 million versus the consensus estimate of $12.62 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.